nuplazid - Acadia Pharmaceuticals
... clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The clinical trial database for NUPLAZID consists of over 1200 subjects and patients exposed to one or more doses of NUPLAZID. Of these, 616 were ...
... clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The clinical trial database for NUPLAZID consists of over 1200 subjects and patients exposed to one or more doses of NUPLAZID. Of these, 616 were ...
TRIAL PHASES:
... information about efficacy and safety that is needed for further risk/benefit assessment of the drug. In this phase, clinical trials are also conducted in special patient populations (e.g., renal failure patients), or under special conditions dictated by the nature of the drug and disease. ...
... information about efficacy and safety that is needed for further risk/benefit assessment of the drug. In this phase, clinical trials are also conducted in special patient populations (e.g., renal failure patients), or under special conditions dictated by the nature of the drug and disease. ...
Antihistamine use in children
... action, absorption, onset and duration of action of first-generation and second-generation H(1)-antihistamines, as well as elimination of H(1)-antihistamines which has important implications for dosing in children. The rationale for the use of H(1)-antihistamines is explored for the relief of histam ...
... action, absorption, onset and duration of action of first-generation and second-generation H(1)-antihistamines, as well as elimination of H(1)-antihistamines which has important implications for dosing in children. The rationale for the use of H(1)-antihistamines is explored for the relief of histam ...
Homeopathic drugs
... The body’s self-healing powers were to be properly activated only by minimal doses of the medicinal substance. The homeopath’s task is not to diagnose the causes of morbidity, but to find the drug with a “symptom profile” most closely resembling that of the patient’s illness. This drug is then appl ...
... The body’s self-healing powers were to be properly activated only by minimal doses of the medicinal substance. The homeopath’s task is not to diagnose the causes of morbidity, but to find the drug with a “symptom profile” most closely resembling that of the patient’s illness. This drug is then appl ...
Product Information: Palonosetron hydrochloride
... A Phase 2, double-blind, dose-ranging study evaluated the efficacy of single-dose IV palonosetron from 0.3 to 90 µg/kg (equivalent to < 0.1 mg to 6 mg fixed dose) in 161 chemotherapy-naïve adult cancer patients receiving highly-emetogenic chemotherapy (either cisplatin ≥ 70 mg/m² or cyclophosphamide ...
... A Phase 2, double-blind, dose-ranging study evaluated the efficacy of single-dose IV palonosetron from 0.3 to 90 µg/kg (equivalent to < 0.1 mg to 6 mg fixed dose) in 161 chemotherapy-naïve adult cancer patients receiving highly-emetogenic chemotherapy (either cisplatin ≥ 70 mg/m² or cyclophosphamide ...
Phil Rowe Reader in pharmaceutical computing School of
... • No absorption stage - immediate effect without delay • Guaranteed 100% bioavailability - no variation between patients Disadvantages: • Person administering dose needs careful training ...
... • No absorption stage - immediate effect without delay • Guaranteed 100% bioavailability - no variation between patients Disadvantages: • Person administering dose needs careful training ...
, NEW REASON * TO SWITCH TO CARDIZEM CD 0""
... bacteria No evidence of impaired fertility was observed in a study perlormed in male and female rals al oral dosages ol up to 100 mg/kg/day. Ptennanrx Category C. Reproduction studies have been conducted in mice, rats, and rabbits. Administration of doses ranging from live to ten limes greater (on a ...
... bacteria No evidence of impaired fertility was observed in a study perlormed in male and female rals al oral dosages ol up to 100 mg/kg/day. Ptennanrx Category C. Reproduction studies have been conducted in mice, rats, and rabbits. Administration of doses ranging from live to ten limes greater (on a ...
PACKAGE LEAFLET TINIDAZOL ATC code
... For treatment of anaerobic infections in adults: a single dose of 2 g on the first day and a single dose of 1 g or two doses of 500 mg during the next days. The duration of treatment is from 5 to 7 days. For nonspecific vaginites in women: a single dose of 2 g or twice daily of 1 g for 2 days. For a ...
... For treatment of anaerobic infections in adults: a single dose of 2 g on the first day and a single dose of 1 g or two doses of 500 mg during the next days. The duration of treatment is from 5 to 7 days. For nonspecific vaginites in women: a single dose of 2 g or twice daily of 1 g for 2 days. For a ...
Cefdinir Use in Children - University of Virginia School of Medicine
... Cefdinir is eliminated primarily through renal excretion; it undergoes minimal metabolism. The mean plasma elimination half-life in healthy adults is 1.7 + 0.6 hours, with a renal clearance of 2 + 1 mL/min/kg. In a single-dose pharmacokinetic study conducted in children 6 months to 12 years of age, ...
... Cefdinir is eliminated primarily through renal excretion; it undergoes minimal metabolism. The mean plasma elimination half-life in healthy adults is 1.7 + 0.6 hours, with a renal clearance of 2 + 1 mL/min/kg. In a single-dose pharmacokinetic study conducted in children 6 months to 12 years of age, ...
Roxipharm
... Roxipharm® (Roxithromycin) is a semisynthetic macrolide antibiotic that acts as an antibacterial by inhibition of protein synthesis. It has a broad antibacterial action against many gram - positive and to a lesser extent some gram - negative bacteria, as well as other organisms including anaerobes, ...
... Roxipharm® (Roxithromycin) is a semisynthetic macrolide antibiotic that acts as an antibacterial by inhibition of protein synthesis. It has a broad antibacterial action against many gram - positive and to a lesser extent some gram - negative bacteria, as well as other organisms including anaerobes, ...
rotherham area prescribing committee
... Following meeting 20 September 2006 HOT TOPIC 1: Ivabradine Ivabradine (Procoralan) is a new drug for the symptomatic treatment of chronic stable angina. It is licensed only for people with normal sinus rhythm who have a contraindication or intolerance to beta-blockers. It is a selective sinus node ...
... Following meeting 20 September 2006 HOT TOPIC 1: Ivabradine Ivabradine (Procoralan) is a new drug for the symptomatic treatment of chronic stable angina. It is licensed only for people with normal sinus rhythm who have a contraindication or intolerance to beta-blockers. It is a selective sinus node ...
Drugs used to treat Bipolar Disorder
... Other reasons patients refuse meds: -weight gain - less energy, productivity - feel disease has resolved, no longer need medication Relapse rate is high regardless of withdrawal being gradual or acute, suicide risk back up episodes are often worse than original symptoms, so treatment is often life-l ...
... Other reasons patients refuse meds: -weight gain - less energy, productivity - feel disease has resolved, no longer need medication Relapse rate is high regardless of withdrawal being gradual or acute, suicide risk back up episodes are often worse than original symptoms, so treatment is often life-l ...
Histasin
... Cetirizine, a human metabolite of hydroxyzine, is a potent and selective antagonist of peripheral H 1receptors. In vitro receptor binding studies have shown no measurable affinity for other than H1receptors. In addition to its anti-H1 effect, cetirizine was shown to display anti-allergic activities: ...
... Cetirizine, a human metabolite of hydroxyzine, is a potent and selective antagonist of peripheral H 1receptors. In vitro receptor binding studies have shown no measurable affinity for other than H1receptors. In addition to its anti-H1 effect, cetirizine was shown to display anti-allergic activities: ...
aspirin (acetylsalicylic acid, ASA)L L(ass-purr
... Baseline Assessment: Do not give to children/teenagers who have flu or chicken pox (increases risk of Reye’s syndrome). Do not use if vinegarlike odor is noted (indicates chemical breakdown). Assess type, location, duration of pain, inflammation. Inspect appearance of affected joints for immobility, ...
... Baseline Assessment: Do not give to children/teenagers who have flu or chicken pox (increases risk of Reye’s syndrome). Do not use if vinegarlike odor is noted (indicates chemical breakdown). Assess type, location, duration of pain, inflammation. Inspect appearance of affected joints for immobility, ...
Accurate dose means effective therapy
... However, there are no standardised methodologies that accurately relate the radioactivity of the drug administered to the patient to the actual dose delivered. The current approach, called “as high as safely administered” is based on generic responses of patients during clinical trials. It ensures p ...
... However, there are no standardised methodologies that accurately relate the radioactivity of the drug administered to the patient to the actual dose delivered. The current approach, called “as high as safely administered” is based on generic responses of patients during clinical trials. It ensures p ...
Nivalis Therapeutics, Inc. Investor Presentation March 2016
... • N91115 added to Orkambi in CF adults who are homozygous for F508del • Double-blind, randomized, placebo controlled, parallel group study • Three arms, 45 patients per arm, total 135 ...
... • N91115 added to Orkambi in CF adults who are homozygous for F508del • Double-blind, randomized, placebo controlled, parallel group study • Three arms, 45 patients per arm, total 135 ...
Review-Medicine and Drugs
... o What is a drug or medicine? § Alter mood or emotions § Alter a physiological state § Alter incoming sensory sensations o Administer drugs: § Oral § Rectal § Inhalation § Injection § Patches o LD50: § See how toxic a molecule might be (smallest is the most toxic) § Lethal Dose: a substance that kil ...
... o What is a drug or medicine? § Alter mood or emotions § Alter a physiological state § Alter incoming sensory sensations o Administer drugs: § Oral § Rectal § Inhalation § Injection § Patches o LD50: § See how toxic a molecule might be (smallest is the most toxic) § Lethal Dose: a substance that kil ...
Biol. Psychist. __, No.3, pp.243-246 (1972).
... and waking time appeared only as nonsignificant trends. In the high dose group, percent of REM sleep was markedly increased, due to early onset of stage REM and to increased duration of REM episodes during the second half of the night. EEG sleep patterns on recovery nights following large doses of t ...
... and waking time appeared only as nonsignificant trends. In the high dose group, percent of REM sleep was markedly increased, due to early onset of stage REM and to increased duration of REM episodes during the second half of the night. EEG sleep patterns on recovery nights following large doses of t ...
Spherix Announces Positive Phase 2 Study Results
... biotechnology and pharmaceutical companies, today announced positive preliminary results from a Phase 2 clinical trial of its novel compound, Naturlose® (D-tagatose), in the treatment and management of Type 2 diabetes. The Phase 2 trial is expected to be completed in early 2010. In the ongoing singl ...
... biotechnology and pharmaceutical companies, today announced positive preliminary results from a Phase 2 clinical trial of its novel compound, Naturlose® (D-tagatose), in the treatment and management of Type 2 diabetes. The Phase 2 trial is expected to be completed in early 2010. In the ongoing singl ...
HVPA Rx New Drug Update July 2004 Ketek® (telithromycin
... Significant Drug Interaction Potential: • Patients taking telithromycin should avoid concomitant use of: simvastatin, lovastatin, or atorvastatin. Patients should cease taking these agents during therapy with telithromycin. • In patients treated with metoprolol for heart failure, the increased exp ...
... Significant Drug Interaction Potential: • Patients taking telithromycin should avoid concomitant use of: simvastatin, lovastatin, or atorvastatin. Patients should cease taking these agents during therapy with telithromycin. • In patients treated with metoprolol for heart failure, the increased exp ...
ThromboGenics Announces FDA Acceptance of Investigational New
... 10.1% of patients receiving placebo (p<0.01). The Phase III program also showed that JETREA(R) was generally well tolerated with most adverse events being transient and mild in severity. In March 2015, ThromboGenics reported top line results from OASIS, a Phase IIIb study. This randomized, sham cont ...
... 10.1% of patients receiving placebo (p<0.01). The Phase III program also showed that JETREA(R) was generally well tolerated with most adverse events being transient and mild in severity. In March 2015, ThromboGenics reported top line results from OASIS, a Phase IIIb study. This randomized, sham cont ...
Indirect Pharmacodynamic Models for Tolerance
... IL12 produces tolerance rapidly (3-4 days) during multiple dosing which lasts for a relatively long time period (14 days) in humans. PK/PD modeling to characterize schedule-dependent IL12-induced IFNg production is crucial for designing safe and effective dosing regimens. ...
... IL12 produces tolerance rapidly (3-4 days) during multiple dosing which lasts for a relatively long time period (14 days) in humans. PK/PD modeling to characterize schedule-dependent IL12-induced IFNg production is crucial for designing safe and effective dosing regimens. ...
PUBLIC ASSESSMENT REPORT Scientific Discussion
... metabolite perindoprilat. The plasma half-life of perindopril is equal to 1 hour. The peak plasma concentration of perindoprilat is achieved within 3 to 4 hours. - As ingestion of food decreases conversion to perindoprilat, hence bioavailability, perindopril should be administered orally in a single ...
... metabolite perindoprilat. The plasma half-life of perindopril is equal to 1 hour. The peak plasma concentration of perindoprilat is achieved within 3 to 4 hours. - As ingestion of food decreases conversion to perindoprilat, hence bioavailability, perindopril should be administered orally in a single ...
Mobicam - Beximco Pharmaceuticals Ltd.
... The recommended dose for primary dysmenorrhea is 20 to 40 mg once daily. For post-operative pain the recommended dose is 40 mg once daily up to five days and for acute attacks of gout the recommended dose is 40 mg once daily for two days followed by 20 mg once daily for a further five days. Note: Te ...
... The recommended dose for primary dysmenorrhea is 20 to 40 mg once daily. For post-operative pain the recommended dose is 40 mg once daily up to five days and for acute attacks of gout the recommended dose is 40 mg once daily for two days followed by 20 mg once daily for a further five days. Note: Te ...
Bilastine
Bilastine (trade name Bilaxten) is a second generation antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria (hives).It exerts its effect as a selective histamine H1 receptor antagonist, and has a effectiveness similar to cetirizine, fexofenadine and desloratadine. It was developed in Spain by FAES Farma.Bilastine is approved in the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria, but it is not approved by the U.S. Food and Drug Administration for any use in the United States. Bilastine meets the current European Academy of Allergy and Clinical Immunology (EAACI) and Allergic Rhinitis and its Impact of Asthma (ARIA) criteria for medication used in the treatment of allergic rhinitis.Bilastine has been effective in the treatment of ocular symptoms and diseases of allergies, including rhinoconjuctivitis. Additionally, bilastine has been shown to improve quality of life, and all nasal and ocular symptoms related to allergic rhinitis.